Clinical Trials
11
Active:0
Completed:9
Trial Phases
3 Phases
Phase 1:6
Phase 3:4
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (54.5%)Phase 3
4 (36.4%)Phase 4
1 (9.1%)Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
Phase 4
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-06-29
- Target Recruit Count
- 100
- Registration Number
- NCT06922643
Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company
Phase 1
Not yet recruiting
- Conditions
- Natural Blood and Blood Product Toxicity
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 44
- Registration Number
- NCT06919861
Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- Biological: Stimus
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2025-03-30
- Target Recruit Count
- 43
- Registration Number
- NCT05636891
- Locations
- 🇻🇳
NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City, Vietnam
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
Phase 3
Completed
- Conditions
- Chronic Kidney Disease Requiring Chronic DialysisAnemia
- Interventions
- Biological: Stimus (NNG-DEPO)
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 214
- Registration Number
- NCT05585645
- Locations
- 🇻🇳
NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City, Vietnam
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Phase 3
Completed
- Conditions
- Breast Cancer MetastaticBreast Cancer RecurrentBreast Cancer Female
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2023-02-27
- Target Recruit Count
- 128
- Registration Number
- NCT05301010
- Locations
- 🇻🇳
19-8 Hospital, Hanoi, Vietnam
🇻🇳HCMC Oncology Hospital, Ho Chi Minh City, Vietnam
- Prev
- 1
- 2
- 3
- Next
News
No news found